Valneva SE (NASDAQ:VALN – Get Free Report)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $7.18, but opened at $7.48. Valneva shares last traded at $7.48, with a volume of 3,236 shares traded.
Analysts Set New Price Targets
VALN has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and set a $26.00 target price on shares of Valneva in a research report on Friday, May 31st. Guggenheim decreased their price target on shares of Valneva from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, March 22nd.
Check Out Our Latest Report on VALN
Valneva Price Performance
Valneva (NASDAQ:VALN – Get Free Report) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $0.89 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.12. The company had revenue of $35.56 million during the quarter, compared to analyst estimates of $95.80 million. Valneva had a negative net margin of 15.88% and a negative return on equity of 14.56%. On average, research analysts forecast that Valneva SE will post -0.56 EPS for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Valneva stock. General American Investors Co. Inc. lifted its holdings in shares of Valneva SE (NASDAQ:VALN – Free Report) by 2.7% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 354,361 shares of the company’s stock after buying an additional 9,361 shares during the period. General American Investors Co. Inc. owned 0.51% of Valneva worth $2,831,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.39% of the company’s stock.
Valneva Company Profile
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
See Also
- Five stocks we like better than Valneva
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Why These 3 Stocks Are Getting Upgraded by Analysts
- 3 Tickers Leading a Meme Stock Revival
- Target Stock Tumble: Opportunity Knocks for Value Investors
- What is MarketRankā¢? How to Use it
- Risk Tolerance vs Risk Capacity: Key Differences & How to Measure
Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.